BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32109988)

  • 1. Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression.
    Xia B; Wang J
    Drug Des Devel Ther; 2019; 13():3837-3844. PubMed ID: 32109988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
    Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
    Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.
    Niu H; Wu B; Peng Y; Jiang H; Zhang Y; Wang J; Zhang Y; He P
    Tumour Biol; 2015 Jan; 36(1):409-19. PubMed ID: 25266803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.
    Ghosh S; Maity P
    J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer.
    Koh SA; Kim MK; Lee KH; Kim SW; Kim JR
    Clin Exp Metastasis; 2014 Oct; 31(7):805-15. PubMed ID: 25253431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.
    Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D
    Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
    Fang Y; Yi J; Lizhi L; Qiucheng C
    DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway.
    Zhang M; Ding G; Zhou L; Shen T; Xu X; Zhao T; Jia S; Cao L
    J Interferon Cytokine Res; 2018 Sep; 38(9):413-422. PubMed ID: 30192158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of RhoGDI2 mediated lung cancer epithelial-mesenchymal transition suppression.
    Niu H; Wu B; Jiang H; Li H; Zhang Y; Peng Y; He P
    Cell Physiol Biochem; 2014; 34(6):2007-16. PubMed ID: 25562149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleuromutilin Inhibits Proliferation and Migration of A2780 and Caov-3 Ovarian Carcinoma Cells and Growth of Mouse A2780 Tumor Xenografts by Down-Regulation of pFAK2.
    Zhang B; Ma X; Li Y; Li S; Cheng J
    Med Sci Monit; 2020 Feb; 26():e920407. PubMed ID: 32041931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.
    Cho HJ; Park SM; Kim IK; Nam IK; Baek KE; Im MJ; Yoo JM; Park SH; Ryu KJ; Han HT; Kim HJ; Hong SC; Kim KD; Pak Y; Kim JW; Lee CW; Yoo J
    Oncotarget; 2014 Mar; 5(6):1554-64. PubMed ID: 24721928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway.
    Xu M; Zhang Y
    Anticancer Agents Med Chem; 2019; 19(18):2243-2250. PubMed ID: 31660844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RhoGDI stability is regulated by SUMOylation and ubiquitination via the AT1 receptor and participates in Ang II-induced smooth muscle proliferation and vascular remodeling.
    Dai F; Qi Y; Guan W; Meng G; Liu Z; Zhang T; Yao W
    Atherosclerosis; 2019 Sep; 288():124-136. PubMed ID: 31362179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
    Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
    Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer.
    Wu B; Hu K; Li S; Zhu J; Gu L; Shen H; Hambly BD; Bao S; Di W
    Oncol Rep; 2012 Jan; 27(1):101-8. PubMed ID: 22025319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.